Amplia Therapeutics Limited Logo

Amplia Therapeutics Limited

INNMF

(1.2)
Stock Price

0,06 USD

-73.37% ROA

-34.42% ROE

-6.49x PER

Market Cap.

45.289.007,71 USD

13.68% DER

0% Yield

-101.14% NPM

Amplia Therapeutics Limited Stock Analysis

Amplia Therapeutics Limited Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Amplia Therapeutics Limited Fundamental Stock Analysis
# Analysis Rating
1 PBV

With a remarkably low PBV ratio (0.47x), the stock offers substantial upside potential at a bargain price.

2 DER

The stock has a minimal amount of debt (14%) relative to its ownership, showcasing a strong financial position and lower risk for investors.

3 Graham Number

The company's Graham number indicates that it is undervalued compared to its stock price, suggesting a potentially favorable investment opportunity.

4 ROE

Negative ROE (-33.13%) indicates poor financial performance, raising concerns about profitability and efficiency in utilizing shareholders' equity.

5 ROA

The stock's ROA (-58.09%) indicates that it's not effectively utilizing its assets to generate profits, making it a less favorable option to invest and earn consistent returns.

6 Revenue Growth

Regrettably, this company's revenue has shown no signs of growth over the past three years, suggesting limited potential for returns and making it a less appealing choice.

7 Net Profit Growth

Despite the passage of five years, this company's net profit has not shown any improvement, highlighting a lack of growth and making it a less appealing investment prospect.

8 Assets Growth

Company has experienced no growth in revenue over the past three years, suggesting limited profitability and making it a less desirable investment opportunity.

9 Dividend Growth

The company's dividend growth has been flat for the past three years, raising concerns for potential investors seeking reliable returns.

10 Dividend

Investors should note the absence of dividends from the company in the last three years, indicating potential financial challenges.

11 Buffet Intrinsic Value

The company's stock shows signs of being overvalued (0) according to Warren Buffett's formula, indicating a potential downside as its market price exceeds its estimated intrinsic value.

Amplia Therapeutics Limited Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Amplia Therapeutics Limited Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Hold
2 MACD Sell
3 RSI Hold
4 Stoch RSI Sell

Amplia Therapeutics Limited Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Amplia Therapeutics Limited Revenue
Year Revenue Growth
2013 0
2014 0 0%
2015 30.309 100%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 34.227 100%
2021 1.533.521 97.77%
2022 1.983.316 22.68%
2023 1.189.486 -66.74%
2024 0 0%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Amplia Therapeutics Limited Research and Development Expenses
Year Research and Development Expenses Growth
2013 0
2014 648.000 100%
2015 2.041.000 68.25%
2016 4.746.000 57%
2017 6.036.000 21.37%
2018 3.416.000 -76.7%
2019 736.000 -364.13%
2020 1.072.000 31.34%
2021 2.212.000 51.54%
2022 3.772.156 41.36%
2023 4.686.887 19.52%
2024 14.443.896 67.55%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Amplia Therapeutics Limited General and Administrative Expenses
Year General and Administrative Expenses Growth
2013 0
2014 1.746.000 100%
2015 1.602.000 -8.99%
2016 1.476.000 -8.54%
2017 2.393.000 38.32%
2018 1.429.000 -67.46%
2019 1.048.000 -36.35%
2020 1.061.000 1.23%
2021 1.349.000 21.35%
2022 1.697.004 20.51%
2023 2.407.523 29.51%
2024 0 0%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Amplia Therapeutics Limited EBITDA
Year EBITDA Growth
2013 0
2014 -2.527.000 100%
2015 -3.881.000 34.89%
2016 -6.743.000 42.44%
2017 -8.931.000 24.5%
2018 -4.947.000 -80.53%
2019 -1.939.000 -155.13%
2020 -2.256.000 14.05%
2021 -3.873.000 41.75%
2022 -3.639.858 -6.41%
2023 -6.115.219 40.48%
2024 -21.480.240 71.53%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Amplia Therapeutics Limited Gross Profit
Year Gross Profit Growth
2013 0
2014 0 0%
2015 30.309 100%
2016 -568.416 105.33%
2017 -36.952 -1438.26%
2018 -20.161 -83.28%
2019 -1.590 -1167.99%
2020 33.425 104.76%
2021 1.532.848 97.82%
2022 1.980.106 22.59%
2023 1.116.118 -77.41%
2024 -172.800 745.9%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Amplia Therapeutics Limited Net Profit
Year Net Profit Growth
2013 0
2014 -4.495.000 100%
2015 -5.237.000 14.17%
2016 -4.943.000 -5.95%
2017 -7.076.000 30.14%
2018 -4.298.000 -64.63%
2019 -1.870.000 -129.84%
2020 -2.219.000 15.73%
2021 -2.281.000 2.72%
2022 -3.644.217 37.41%
2023 -6.242.435 41.62%
2024 -13.496.840 53.75%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Amplia Therapeutics Limited Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2013 0
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%
2024 0 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Amplia Therapeutics Limited Free Cashflow
Year Free Cashflow Growth
2013 0
2014 -1.605.621 100%
2015 -4.002.757 59.89%
2016 -4.753.319 15.79%
2017 -6.208.004 23.43%
2018 -3.553.000 -74.73%
2019 -990.348 -258.76%
2020 -2.087.977 52.57%
2021 -2.921.255 28.52%
2022 -4.416.421 33.85%
2023 -5.307.319 16.79%
2024 -1.586.628 -234.5%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Amplia Therapeutics Limited Operating Cashflow
Year Operating Cashflow Growth
2013 0
2014 -1.604.621 100%
2015 -3.977.757 59.66%
2016 -4.714.319 15.62%
2017 -6.162.004 23.49%
2018 -3.549.000 -73.63%
2019 -987.348 -259.45%
2020 -2.087.977 52.71%
2021 -2.916.255 28.4%
2022 -4.402.019 33.75%
2023 -5.289.688 16.78%
2024 -1.584.402 -233.86%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Amplia Therapeutics Limited Capital Expenditure
Year Capital Expenditure Growth
2013 0
2014 1.000 100%
2015 25.000 96%
2016 39.000 35.9%
2017 46.000 15.22%
2018 4.000 -1050%
2019 3.000 -33.33%
2020 0 0%
2021 5.000 100%
2022 14.402 65.28%
2023 17.631 18.31%
2024 2.226 -692.05%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Amplia Therapeutics Limited Equity
Year Equity Growth
2013 11.235.000
2014 9.772.478 -14.97%
2015 4.866.037 -100.83%
2016 4.003.279 -21.55%
2017 6.628.956 39.61%
2018 2.364.248 -180.38%
2019 8.664.475 72.71%
2020 8.605.765 -0.68%
2021 10.339.959 16.77%
2022 21.847.638 52.67%
2023 15.835.526 -37.97%
2024 11.418.309 -38.69%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Amplia Therapeutics Limited Assets
Year Assets Growth
2013 11.426.000
2014 10.176.209 -12.28%
2015 5.318.933 -91.32%
2016 5.034.636 -5.65%
2017 7.536.829 33.2%
2018 2.643.670 -185.09%
2019 9.191.334 71.24%
2020 9.116.385 -0.82%
2021 10.879.089 16.2%
2022 24.483.701 55.57%
2023 18.684.335 -31.04%
2024 14.845.108 -25.86%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Amplia Therapeutics Limited Liabilities
Year Liabilities Growth
2013 191.000
2014 403.731 52.69%
2015 452.896 10.86%
2016 1.031.357 56.09%
2017 907.873 -13.6%
2018 279.422 -224.91%
2019 526.859 46.96%
2020 510.620 -3.18%
2021 539.130 5.29%
2022 2.636.063 79.55%
2023 2.848.809 7.47%
2024 3.426.799 16.87%

Amplia Therapeutics Limited Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
0.01
Net Income per Share
-0.03
Price to Earning Ratio
-6.49x
Price To Sales Ratio
18.5x
POCF Ratio
-4.77
PFCF Ratio
-6.56
Price to Book Ratio
2.88
EV to Sales
17.75
EV Over EBITDA
-4.58
EV to Operating CashFlow
-6.3
EV to FreeCashFlow
-6.3
Earnings Yield
-0.15
FreeCashFlow Yield
-0.15
Market Cap
0,05 Bil.
Enterprise Value
0,04 Bil.
Graham Number
0.18
Graham NetNet
0.01

Income Statement Metrics

Net Income per Share
-0.03
Income Quality
1.36
ROE
-0.37
Return On Assets
-0.3
Return On Capital Employed
-0.61
Net Income per EBT
0.5
EBT Per Ebit
1.29
Ebit per Revenue
-1.56
Effective Tax Rate
0.5

Margins

Sales, General, & Administrative to Revenue
0.5
Research & Developement to Revenue
2.82
Stock Based Compensation to Revenue
0.02
Gross Profit Margin
0.92
Operating Profit Margin
-1.56
Pretax Profit Margin
-2.01
Net Profit Margin
-1.01

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
-0.03
Free CashFlow per Share
-0.03
Capex to Operating CashFlow
-0
Capex to Revenue
0
Capex to Depreciation
0.02
Return on Invested Capital
-0.39
Return on Tangible Assets
-0.73
Days Sales Outstanding
473.72
Days Payables Outstanding
4125.61
Days of Inventory on Hand
0
Receivables Turnover
0.77
Payables Turnover
0.09
Inventory Turnover
0
Capex per Share
0

Balance Sheet

Cash per Share
0,02
Book Value per Share
0,06
Tangible Book Value per Share
0.02
Shareholders Equity per Share
0.06
Interest Debt per Share
0.01
Debt to Equity
0.14
Debt to Assets
0.11
Net Debt to EBITDA
0.19
Current Ratio
1.98
Tangible Asset Value
0,00 Bil.
Net Current Asset Value
0,00 Bil.
Invested Capital
11388630
Working Capital
0,00 Bil.
Intangibles to Total Assets
0.53
Average Receivables
0,00 Bil.
Average Payables
0,00 Bil.
Average Inventory
0
Debt to Market Cap
0.03

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Amplia Therapeutics Limited Dividends
Year Dividends Growth

Amplia Therapeutics Limited Profile

About Amplia Therapeutics Limited

Amplia Therapeutics Limited, a pharmaceutical company, focuses on development of focal adhesion kinase (FAK) inhibitors for oncology and chronic fibrosis in Australia. The company's product pipeline includes AMP945, an inhibitor of FAK, for pancreatic cancer and idiopathic pulmonary fibrosis, as well as other cancers and fibrotic diseases indications, that has completed Phase I clinical trial; and AMP886 for cancer and fibrotic disease indication. It has a collaboration agreement with the Garvan Institute of Media Research in Sydney. The company was formerly known as Innate Immunotherapeutics Limited and changed its name to Amplia Therapeutics Limited in September 2018. Amplia Therapeutics Limited was incorporated in 2000 and is headquartered in Melbourne, Australia.

CEO
Dr. Christopher J. Burns B.Sc.
Employee
0
Address
350 Queen Street
Melbourne, 3000

Amplia Therapeutics Limited Executives & BODs

Amplia Therapeutics Limited Executives & BODs
# Name Age
1 Mr. Timothy Luscombe B.Com., C.A.
Chief Financial Officer
70
2 Dr. Christopher J. Burns B.Sc., BSc(Hons), Ph.D.
Chief Executive Officer, MD & Director
70
3 Mr. Andrew John Cooke FAICS, FCIS, FGIA, L.L.B., LLB, MAICD
Company Secretary
70
4 Ms. Rhiannon Jones B.Sc., Ph.D.
Chief Operating Officer
70

Amplia Therapeutics Limited Competitors